Phase II study of capecitabine in combination with oxaliplatin and radiotherapy for esophageal and gastroesophageal junction cancer.

Trial Profile

Phase II study of capecitabine in combination with oxaliplatin and radiotherapy for esophageal and gastroesophageal junction cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Capecitabine (Primary) ; Capecitabine (Primary) ; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2012 Planned End Date changed from 1 Apr 2010 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 09 Mar 2011 Planned end date changed from 1 Sep 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top